Researchers exploit rhythm of DNA replication to kill cancer cells

New DNA is generated in human cells from tiny building blocks called nucleotides produced by an enzyme called RNR. Until now, we have not fully understood how exactly the RNR rhythm and the presence of right amount of nucleotides are aligned with the pace of DNA replication. Now, researchers from the Faculty of Health and Medical Sciences at the University of Copenhagen have mapped the flow and regulation of nucleotides. The flow follows the same rhythm as replication of DNA does - and when it does not, the cells regulate the process to align the two.

"We can see that these processes follow the same periodic rhythm. We found a mechanism that instantly slows down DNA-replication when RNR, the nucleotide factory, gets out of that rhythm, but well before the nucleotide supply becomes critically low, says Jiri Lukas Professor and Executive Director at The Novo Nordisk Foundation Center for Protein Research.

Building blocks catching up

The research groups led by Professors Jiri Lukas and Chunaram Choudhary found that the cell reacts to even small changes in the flow of nucleotides. If the production falters, a chemical signal consisting of reactive oxygen species (ROS) spreads the message to slow down the DNA replication.

Their research paper; published today in the journal Science, reports that such communication between nucleotide supply and DNA replication speed is possible thanks to the fact that all sites in human genome that actively copy DNA contain a protein called PRDX2 that senses this chemical alert.

When this happens, the PRDX2 protein releases an accelerator called TIMELESS from the DNA, and this release slows down the pace with which cell cope their DNA. Slower DNA replications allows for the production of nucleotides to catch up and get back to the same rhythm with DNA synthesis. Because of this, there are almost always enough nucleotides to build the DNA, which is turn is critically important for the copying the healthy genomes without mistakes.

High speed kills cancer

This finding sheds light on several illnesses, but is especially important in relation to cancer. The researchers show that they can deactivate the chemical signal that alerts the cells to problems with nucleotide production. Under such conditions, cells cannot slow down the replication process, and the researchers propose that this would impede proliferation of cancer cells because they are particularly vulnerable to a high replication speed.

"We found that cancer cells copy their DNA rather slow, because they have abnormal genomes and replicating DNA has to overcome many obstacles. When we remove their ability to copy their genomes slowly, the cancer cells die because they cannot cope with too many bumps on their DNA templates," says Kumar Somyajit, Post.Doc and first author of the study.

Kumar Somyajit, Rajat Gupta, Hana Sedlackova, Kai John Neelsen, Fena Ochs, Maj-Britt Rask, Chunaram Choudhary, Jiri Lukas.
Redox-sensitive alteration of replisome architecture safeguards genome integrity.
Science, Vol. 358, Issue 6364, pp. 797-802. doi: 10.1126/science.aao3172.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

A great place to do great things: Developing game-…

Science has spoken: Abbott (NYSE: ABT) is, again, among the best science-based companies to work for in the world. For the 14th year, the journal Science today recognized...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Scientists find where HIV 'hides' to evade detecti…

In a decades-long game of hide and seek, scientists from Sydney's Westmead Institute for Medical Research have confirmed for the very first time the specific immune memor...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]